A global medical isotope supply observatory with forecasts and shortage alerts
Nobody publishes how much cancer isotope is made, where, or when supply will fall short. A public observatory would let hospitals and investors plan.
Overview
Supply and demand for lutetium-177, actinium-225, iodine-131 and their precursors are opaque; producers guard volumes, and shortages surface only when clinics cancel doses. The proposal is an observatory, hosted by the IAEA or OECD NEA with WHO, that collects confidential production and capacity data from producers under aggregation rules, publishes quarterly supply-demand balances and five-year forecasts, and issues shortage alerts to clinics and regulators. It would also track trial-stage demand so producers can invest ahead of approvals.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
Similar pages
not linked directly; found by shared links- IdeaA coordinated reserve and shared schedule for the world's medical isotope reactors
Shares Molybdenum-99 supply, Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Manufacturing cost and time for living and radioactive medicines, Iodine-131.
- IdeaRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
Shares Actinium-225 supply, Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Manufacturing cost and time for living and radioactive medicines, Targeted alpha therapy.
- CompanyNorthStar Medical Radioisotopes
Shares Molybdenum-99 supply, Actinium-225 supply, Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Actinium-225.
- CompanySHINE Technologies
Shares Molybdenum-99 supply, Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Actinium-225, Lutetium-177.
- CompanyTerraPower Isotopes
Shares Actinium-225 supply, Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Manufacturing cost and time for living and radioactive medicines, Targeted alpha therapy.
- Key paperRadiopharmaceutical therapy in cancer: clinical advances and challenges
Shares Iodine-131, Targeted alpha therapy, Actinium-225, Radioligand therapy (beta emitters).
- CompanyNTP Radioisotopes
Shares Molybdenum-99 supply, Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium, Iodine-131, Lutetium-177.
- IdeaRegional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit
Shares Actinium-225 supply, Manufacturing cost and time for living and radioactive medicines, Targeted alpha therapy, Actinium-225.